Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q15708292> ?p ?o }
Showing triples 1 to 50 of
50
with 100 triples per page.
- Q15708292 subject Q7334131.
- Q15708292 subject Q8282130.
- Q15708292 subject Q8297683.
- Q15708292 subject Q8431759.
- Q15708292 subject Q8802906.
- Q15708292 subject Q8955377.
- Q15708292 subject Q8978033.
- Q15708292 abstract "Cobimetinib (GDC-0973, XL-518, trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.Cobimetinib in combination with vemurafenib is reportedly priced at $17,600 per month, or about $211,000 per year. A competing dual therapy, using dabrafenib along with trametinib, is also approved by the FDA, and is reported to cost $15,300 monthly, or $183,600 per year.".
- Q15708292 atcPrefix "none".
- Q15708292 bioavailability "28.0".
- Q15708292 casNumber "934660-93-2".
- Q15708292 chEBI "90851".
- Q15708292 drugbank "DB05239".
- Q15708292 iupacName "(S)[3,4-Difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl]azetidin-1-yl) methanone".
- Q15708292 pubchem "16222096".
- Q15708292 thumbnail Cobimetinib.svg?width=300.
- Q15708292 wikiPageExternalLink 206192s000lbl.pdf.
- Q15708292 wikiPageWikiLink Q17142288.
- Q15708292 wikiPageWikiLink Q17853226.
- Q15708292 wikiPageWikiLink Q180614.
- Q15708292 wikiPageWikiLink Q21851559.
- Q15708292 wikiPageWikiLink Q3011604.
- Q15708292 wikiPageWikiLink Q38933.
- Q15708292 wikiPageWikiLink Q423111.
- Q15708292 wikiPageWikiLink Q5419989.
- Q15708292 wikiPageWikiLink Q7334131.
- Q15708292 wikiPageWikiLink Q7833138.
- Q15708292 wikiPageWikiLink Q8282130.
- Q15708292 wikiPageWikiLink Q8297683.
- Q15708292 wikiPageWikiLink Q8431759.
- Q15708292 wikiPageWikiLink Q8802906.
- Q15708292 wikiPageWikiLink Q8955377.
- Q15708292 wikiPageWikiLink Q8978033.
- Q15708292 wikiPageWikiLink Q899140.
- Q15708292 wikiPageWikiLink Q899651.
- Q15708292 atcPrefix "none".
- Q15708292 bioavailability "28.0".
- Q15708292 casNumber "934660".
- Q15708292 chebi "90851".
- Q15708292 drugbank "DB05239".
- Q15708292 iupacName "[3,4-Difluoro-2-phenyl][3-hydroxy-3- methanone".
- Q15708292 pubchem "16222096".
- Q15708292 type ChemicalSubstance.
- Q15708292 type Drug.
- Q15708292 type ChemicalObject.
- Q15708292 type Thing.
- Q15708292 type Q8386.
- Q15708292 comment "Cobimetinib (GDC-0973, XL-518, trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf).".
- Q15708292 label "Cobimetinib".
- Q15708292 depiction Cobimetinib.svg.
